USANA Health Sciences (USNA) Tops Q2 EPS by 32c

Go back to USANA Health Sciences (USNA) Tops Q2 EPS by 32c

DA Davidson Downgrades USANA Health Sciences Inc. (USNA) to Neutral

August 6, 2015 7:24 AM EDT

DA Davidson downgraded USANA Health Sciences Inc. (NYSE: USNA) from Buy to Neutral.

For an analyst ratings summary and ratings history on USANA Health Sciences Inc. click here. For more ratings news on USANA Health Sciences Inc. click here.

Shares of USANA Health Sciences Inc. closed at $176.12 yesterday.

... More

Pivotal Research Upgrades USANA Health Sciences Inc. (USNA) to Buy

August 5, 2015 12:52 PM EDT

Pivotal Research upgraded USANA Health Sciences Inc. (NYSE: USNA) from Hold to Buy with a price target of $200. Analyst Timothy S. Ramey noted hyper-growth in China.

"USNA reported 2Q15 EPS of $1.92 vs. $1.36, up 41% on sales growth of 23.9%. That beat our estimate of $1.52 pretty... More

USANA Health Sciences (USNA) Appoints co-CEOs

August 4, 2015 4:18 PM EDT

USANA Health Sciences (NYSE: USNA) announced that the Board of Directors has appointed Dave Wentz and Kevin Guest as Co-Chief Executive Officers of the Company, effective immediately. Mr. Wentz will oversee USANAs global operations, while Mr. Guest will lead USANAs worldwide field development and sales efforts. Both Mr. Guest and Mr. Wentz will report directly to the Board of Directors.

Dr. Myron Wentz, USANAs founder and Chairman of the Board, commented, Kevin has been with USANA for over 20 years, most... More